The outcomes of the SHOCK trial led to a ACC/AHA class 1A recommendation for an early invasive strategy in acute MI complicated by cardiogenic ... ACC/AHA/SCAI 2005 guideline update for ...

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology firm specializing in the development of therapies for critical diseases and currently valued at $1.44 million market ...